Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Onychomycosis (US)

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis (www.pipelinereview.com)
CombinatoRx new combination product- CRx-191 is intriguing in that it combines a topical steroid with nortryptiline to minimize the negative effects of the steroid and make it more potent. This would be useful in that higher potency topical steroids are more effective, but cause more thinning of the...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering (www.pipelinereview.com)
The recently announced collaboartion between Stiefel and Allergan in regards to Tazorac is very positive. Stiefel needs this molecule to put into different dosage forms, and in combination with its existing products espoecially Duac, etc. Their current acne product line is strong, but this will solodify...
November 8, 2007
me too drug!
Analysis of: A.T.S. Pharmaceuticals, A Division Of Auriga Laboratories, Launches Coraz™ Lotion For The Treatment Of Seborrheic Dermatitis (www.medicalnewstoday.com)
Why bother with this branded 2% hydrocortisone lotion?  Likely third tier, and nothing special other than the gimicky wash that goes along with it.  The lotion is a very weak %of steroid- so probably minimally useful. ? pediatric indication, would possibly have some hope for the product.
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Astrup Drug, Inc.
Analysis of: Cough-Medicine Dilemma Widens (online.wsj.com)
An FDA advisory panel recently voted to stop the recommendation of otc cough and cold products in children less than 12 years of age. For decades parents have administered otc cough and could products to infants and young children. Even the FDA Advisory Committee had dissention amongst their members,...
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Astrup Drug, Inc.
October 22, 2007
Exit Exubera
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline (online.wsj.com)
Pfizer failed miserably in its attempt to provide diabetic patients with an easy-to-use inhaled insulin as an alternative to injectable insulin. A product they projected would generate sales of $2 billion a year recorded a disappointing $12 million in sales this year. CEO Kindler said he decided to...
Analysis of: Nonpayment for Performance? Medicare's New Reimbursement Rule (content.nejm.org)
This is an absurdity. 
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study (www.pipelinereview.com)
Abbotts ABT-874 monoclonal antibody for psoriasis shows impressive results in the phase 2 trial. The results were up to 90% of patients achieving at least 75% reduction in their psoriasis. These results are as good or better than those with Remicade the most effective biologic for psoriasis currently....
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Astrup Drug, Inc.
October 1, 2007
New Dose For Old Drug
Analysis of: FDA approves SOMA 250 mg (www.pipelinereview.com)
The FDA recently approved a 250mg Soma® tablet manufactured by MedPointe Pharmaceuticals as a new recommended dose for the treatment of painful musculoskeletal problems such as backache. The drug is not new, in fact it has been around for nearly 50 years, first receiving FDA approval...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Relieva Exceeds Expectations In Recent Clinical Trial For Eczema (Atopic Dermatitis) (www.medicalnewstoday.com)
The recent results for a trial of Relieva in atopic dermatitis or eczema, a cream containing a homeopathic compound, were positive by a report from the company. The study sample was small, and the trial was open label. Generally these trials have a larger number of patients, and are blinded. Also it...
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations
Astrup Drug, Inc.
Analysis of: FDA Okays FluMist Vaccine For Young Children (www.medicalnewstoday.com)
The FDA recently approved the expanded use of FluMist, the only nasal spray influenza vaccine, in children 2 to 5 years of age. Each year in the U.S up to 60 million Americans get the flu according to the CDC. The U.S. CDC recommends all children aged 6 to 59 months be vaccinated against the flu. FluMist...

Previous Page : 1 2 3 4 5 6 7 8 Next31 to 40 of 75

Analytics


Generated at 2009-01-07T19:00:58.307